+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Metastatic Bone Disease Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018-2026

  • ID: 4850978
  • Report
  • June 2018
  • Region: Global
  • 202 pages
  • Transparency Market Research
1 of 2

Global Metastatic Bone Disease Market: Overview

This report analyzes the current and future scenario of the global metastatic bone disease market. Rise in incidence rate of cancer across the world, favorable reimbursement scenario, stringent regulatory policies assuring better product quality, increase in cancer research funding and new drug approvals, and surge in cancer awareness programs by governments and patient support organizations drive the global metastatic bone disease market. The global market has been segmented based on treatment, origin of metastasis, end-user, and region.

The global metastatic bone disease market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market. It also provides information and data analysis of the global market with respect to the segments based on treatment, origin of metastasis, end-user, and region. A detailed qualitative analysis of drivers and restraints of the market and opportunities has been provided in the overview section. Additionally, the section comprises competitive matrix and company profiles along with business overview to understand the competitive landscape in the market. This section of the report also provides market attractiveness analysis by region and market share analysis by key players, thereby presenting a thorough analysis of the overall competitive scenario in the metastatic bone disease market.

Global Metastatic Bone Disease Market: Key Segments

Based on treatment, the global metastatic bone disease market has been segmented into medication, radiation therapy, surgical intervention, and tumor ablation therapy. The medication segment has been classified into chemotherapy, hormone therapy, bisphosphonates, opiate therapy, and immunotherapy. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Based on origin of metastasis, the global metastatic bone disease market has been divided into breast, lung, thyroid, kidney, prostate, and others. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

In terms of end-user, the global the global metastatic bone disease market has been categorized into hospitals, specialty clinics, and ambulatory surgical centers. The segments have been analyzed based on health care infrastructure, government investment, and economic development in the regions. The market size and forecast for each of these segments have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year.

Global Metastatic Bone Disease Market: Regional Outlook

Geographically, the global metastatic bone disease market has been segmented into five major regions and the key countries in the respective region: North America (the U.S. and Canada), Europe (the U.K., Germany, France, Spain, Italy, and Rest of Europe), Asia Pacific (India, China, Japan, and Rest of Asia Pacific), Latin America (Mexico, Brazil, and Rest of Latin America) and Middle East & Africa (South Africa, GCC Countries, and Rest of Middle East & Africa). The market size and forecast for each of these regions and the mentioned countries have been provided for the period from 2016 to 2026, along with their respective CAGRs for the forecast period from 2018 to 2026, considering 2017 as the base year. The research study also covers the competitive scenario in these regions.

Companies Mentioned in the Report

The report also profiles the major players in the market in terms of various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments. Major players operating in the global metastatic bone disease market are Amgen, Inc., Merck & Co., Inc., F. Hoffmann-La Roche Ltd., Novartis AG, Eli Lilly and Company, Bayer AG, Fresenius Kabi AG, BTG plc, Boston Scientific Corporation, and Medtronic. These players are adopting organic and inorganic growth strategies to expand product offerings, strengthen geographical reach, increase customer base, and garner market share.

Note: Product cover images may vary from those shown
2 of 2
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Metastatic Bone Disease Market

4. Market Overview
4.1. Introduction
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Metastatic Bone Disease Market Analysis and Forecast, 2016-2026

5. Market Outlook
5.1. Pipeline Analysis
5.2. Disease Prevalence & Incidence Rate globally with key countries
5.3. Reimbursement Scenario, by Region
5.4. Distribution of procedures global/by region

6. Global Metastatic Bone Disease Market Analysis and Forecasts, by Treatment
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Treatment, 2016-2026
6.3.1. Medication
6.3.1.1. Chemotherapy
6.3.1.2. Hormone Therapy
6.3.1.3. Bisphosphonates
6.3.1.4. Opiate Therapy
6.3.1.5. Immunotherapy
6.3.2. Radiation Therapy
6.3.3. Surgical Intervention
6.3.4. Tumor Ablation Therapy
6.4. Market Attractiveness, by Treatment

7. Global Metastatic Bone Disease Market Analysis and Forecasts, by Origin of Metastasis
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Origin of Metastasis, 2016-2026
7.3.1. Breast
7.3.2. Lung
7.3.3. Thyroid
7.3.4. Kidney
7.3.5. Prostate
7.3.6. Others
7.4. Market Attractiveness, by Origin of Metastasis

8. Global Metastatic Bone Disease Market Analysis and Forecasts, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2016-2026
8.3.1. Hospitals
8.3.2. Specialty Clinics
8.3.3. Ambulatory Surgical Centers
8.4. Market Attractiveness, by End-user

9. Global Metastatic Bone Disease Market Analysis and Forecasts, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness, by Region

10. North America Metastatic Bone Disease Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Treatment, 2016-2026
10.2.1. Medication
10.2.1.1. Chemotherapy
10.2.1.2. Hormone Therapy
10.2.1.3. Bisphosphonates
10.2.1.4. Opiate Therapy
10.2.1.5. Immunotherapy
10.2.2. Radiation Therapy
10.2.3. Surgical Intervention
10.2.4. Tumor Ablation Therapy
10.3. Market Value Forecast, by Origin of Metastasis, 2016-2026
10.3.1. Breast
10.3.2. Lung
10.3.3. Thyroid
10.3.4. Kidney
10.3.5. Prostate
10.3.6. Others
10.4. Market Value Forecast, by End-user, 2016-2026
10.4.1. Hospitals
10.4.2. Specialty Clinics
10.4.3. Ambulatory Surgical Centers
10.5. Market Value Forecast, by Country, 2016-2026
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Treatment
10.6.2. By Origin of Metastasis
10.6.3. By End-user
10.6.4. By Country

11. Europe Metastatic Bone Disease Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Treatment, 2016-2026
11.2.1. Medication
11.2.1.1. Chemotherapy
11.2.1.2. Hormone Therapy
11.2.1.3. Bisphosphonates
11.2.1.4. Opiate Therapy
11.2.1.5. Immunotherapy
11.2.2. Radiation Therapy
11.2.3. Surgical Intervention
11.2.4. Tumor Ablation Therapy
11.3. Market Value Forecast, by Origin of Metastasis, 2016-2026
11.3.1. Breast
11.3.2. Lung
11.3.3. Thyroid
11.3.4. Kidney
11.3.5. Prostate
11.3.6. Others
11.4. Market Value Forecast, by End-user, 2016-2026
11.4.1. Hospitals
11.4.2. Specialty Clinics
11.4.3. Ambulatory Surgical Centers
11.5. Market Value Forecast, by Country/Sub-region, 2016-2026
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Spain
11.5.5. Italy
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Treatment
11.6.2. By Origin of Metastasis
11.6.3. By End-user
11.6.4. By Country/Sub-region

12. Asia Pacific Metastatic Bone Disease Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Treatment, 2016-2026
12.2.1. Medication
12.2.1.1. Chemotherapy
12.2.1.2. Hormone Therapy
12.2.1.3. Bisphosphonates
12.2.1.4. Opiate Therapy
12.2.1.5. Immunotherapy
12.2.2. Radiation Therapy
12.2.3. Surgical Intervention
12.2.4. Tumor Ablation Therapy
12.3. Market Value Forecast, by Origin of Metastasis, 2016-2026
12.3.1. Breast
12.3.2. Lung
12.3.3. Thyroid
12.3.4. Kidney
12.3.5. Prostate
12.3.6. Others
12.4. Market Value Forecast, by End-user, 2016-2026
12.4.1. Hospitals
12.4.2. Specialty Clinics
12.4.3. Ambulatory Surgical Centers
12.5. Market Value Forecast, by Country/Sub-region, 2016-2026
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Treatment
12.6.2. By Origin of Metastasis
12.6.3. By End-user
12.6.4. By Country/Sub-region

13. Latin America Metastatic Bone Disease Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Treatment, 2016-2026
13.2.1. Medication
13.2.1.1. Chemotherapy
13.2.1.2. Hormone Therapy
13.2.1.3. Bisphosphonates
13.2.1.4. Opiate Therapy
13.2.1.5. Immunotherapy
13.2.2. Radiation Therapy
13.2.3. Surgical Intervention
13.2.4. Tumor Ablation Therapy
13.3. Market Value Forecast, by Origin of Metastasis, 2016-2026
13.3.1. Breast
13.3.2. Lung
13.3.3. Thyroid
13.3.4. Kidney
13.3.5. Prostate
13.3.6. Others
13.4. Market Value Forecast, by End-user, 2016-2026
13.4.1. Hospitals
13.4.2. Specialty Clinics
13.4.3. Ambulatory Surgical Centers
13.5. Market Value Forecast, by Country/Sub-region, 2016-2026
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Treatment
13.6.2. By Origin of Metastasis
13.6.3. By End-user
13.6.4. By Country/Sub-region

14. Middle East & Africa Metastatic Bone Disease Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Treatment, 2016-2026
14.2.1. Medication
14.2.1.1. Chemotherapy
14.2.1.2. Hormone Therapy
14.2.1.3. Bisphosphonates
14.2.1.4. Opiate Therapy
14.2.1.5. Immunotherapy
14.2.2. Radiation Therapy
14.2.3. Surgical Intervention
14.2.4. Tumor Ablation Therapy
14.3. Market Value Forecast, by Origin of Metastasis, 2016-2026
14.3.1. Breast
14.3.2. Lung
14.3.3. Thyroid
14.3.4. Kidney
14.3.5. Prostate
14.3.6. Others
14.4. Market Value Forecast, by End-user, 2016-2026
14.4.1. Hospitals
14.4.2. Specialty Clinics
14.4.3. Ambulatory Surgical Centers
14.5. Market Value Forecast, by Country/Sub-region, 2016-2026
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Treatment
14.6.2. By Origin of Metastasis
14.6.3. By End-user
14.6.4. By Country/Sub-region

15. Competition Landscape
15.1. Market Player - Competition Matrix (By Tier and Size of companies)
15.2. Market Share Analysis, by Company (2017)
15.3. Company Profiles
15.3.1. Amgen, Inc.
15.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.1.2. Financial Overview
15.3.1.3. Product Portfolio
15.3.1.4. SWOT Analysis
15.3.1.5. Strategic Overview
15.3.2. Merck & Co., Inc.
15.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.2.2. Financial Overview
15.3.2.3. Product Portfolio
15.3.2.4. SWOT Analysis
15.3.2.5. Strategic Overview
15.3.3. F. Hoffmann-La Roche Ltd
15.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.3.2. Financial Overview
15.3.3.3. Product Portfolio
15.3.3.4. SWOT Analysis
15.3.3.5. Strategic Overview
15.3.4. Novartis AG
15.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.4.2. Financial Overview
15.3.4.3. Product Portfolio
15.3.4.4. SWOT Analysis
15.3.4.5. Strategic Overview
15.3.5. Eli Lilly and Company
15.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.5.2. Financial Overview
15.3.5.3. Product Portfolio
15.3.5.4. SWOT Analysis
15.3.5.5. Strategic Overview
15.3.6. Bayer AG
15.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.6.2. Financial Overview
15.3.6.3. Product Portfolio
15.3.6.4. SWOT Analysis
15.3.6.5. Strategic Overview
15.3.7. Fresenius Kabi AG
15.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.7.2. Financial Overview
15.3.7.3. Product Portfolio
15.3.7.4. SWOT Analysis
15.3.7.5. Strategic Overview
15.3.8. BTG plc.
15.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.8.2. Financial Overview
15.3.8.3. Product Portfolio
15.3.8.4. SWOT Analysis
15.3.8.5. Strategic Overview
15.3.9. Boston Scientific Corporation
15.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.9.2. Financial Overview
15.3.9.3. Product Portfolio
15.3.9.4. SWOT Analysis
15.3.9.5. Strategic Overview
15.3.10. Medtronic
15.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.3.10.2. Financial Overview
15.3.10.3. Product Portfolio
15.3.10.4. SWOT Analysis
15.3.10.5. Strategic Overview
Note: Product cover images may vary from those shown
3 of 2

Loading
LOADING...

Adroll
adroll